| Document |
Document Title |
|
WO/2024/120484A1 |
The present invention is directed to human monoclonal antibodies that bind to epidermal growth factor -like repeats and discoidin I-like domains 3 (EDIL3) and methods of use thereof.
|
|
WO/2024/120461A1 |
The present invention relates to use of CYP3A4/5 inducers in treating or alleviating peripheral neuropathy caused by antibody-drug conjugates, including an administration mode, an administration dosage, and an administration frequency. T...
|
|
WO/2024/120419A1 |
This application discloses compounds of formula (I), which can be inhibitors of KRAS G12D, and their uses.
|
|
WO/2024/121164A1 |
The present invention relates to solid microbeads having an anti-CD28 monoclonal antibody immobilized thereto for use in the local treatment of malignant melanoma, wherein the anti-CD28 monoclonal antibody binds to an epitope on CD28 out...
|
|
WO/2024/120429A1 |
The present invention provides a universal cell for expressing STC1 and a preparation method therefor. The universal pluripotent cell can significantly reduce or escape the recognition and attack of an immune system, particularly the att...
|
|
WO/2024/124088A1 |
Disclosed herein are antibodies or antigen binding fragments thereof that specifically bind human BCMA. Also disclosed are chimeric antigen receptors and chimeric antigen receptor transgenes comprising an antigen binding domain that spec...
|
|
WO/2024/123139A1 |
The present invention relates to: a carrier for delivering oligonucleotides intended for therapeutic use into cells, wherein, to inhibit a target protein or promote expression of a target protein in a cell, a peptide-based conjugate is p...
|
|
WO/2024/121632A1 |
The invention relates to uses of an anti-CD117 antibody drug conjugate (ADC) comprising an anti-CD117 antibody conjugated to an amatoxin via a linker, for targeted conditioning a human patient in need thereof for hematopoietic stem cell ...
|
|
WO/2024/119866A1 |
Disclosed in the present invention are a benzothiazole pyrimidineamine DYRK2 inhibitor, a preparation method therefor, and a use thereof. The compound of the present invention can inhibit the proliferation of cancer cells, and can be use...
|
|
WO/2024/124240A1 |
Therapeutic methods and pharmaceutical compositions for treating a myeloproliferative neoplasm (MPN) with a combination of a MDM2 inhibitor and a JAK inhibitor.
|
|
WO/2024/120405A1 |
The present invention relates to the technical field of gene therapy drugs, and in particular, to a nucleic acid liposome complex capable of targeting leukemia cell loads to inhibit Rapsyn gene expression and use thereof in preparing a d...
|
|
WO/2024/119373A1 |
Provided is use of an aggregation-induced light-emitting engineered mitochondrion in the preparation of a medicament for treating cancer. The aggregation-induced light-emitting engineered mitochondrion is a mitochondrion modified by an a...
|
|
WO/2024/121753A1 |
The specification generally relates to compounds of Formula (I): (I), or a stereoisomer or pharmaceutically salt thereof, wherein G, Ga, Gb, X, Y, R1, R2, Q1, Q2, and Q3 have any of the meanings defined herein, together with compositions...
|
|
WO/2024/120483A1 |
The present application relates to the use of a quinoline compound for treating ovarian cancer, and specifically relates to the use and a method of N-(4-((7-((1-(cyclopentylamino)cyclopropanyl)methoxy)-6-meth
oxyquinolin-4-yl)oxy)-3-fluo...
|
|
WO/2024/123765A1 |
Therapeutic combinations of ADCs that bind to CD123 (e.g., IMGN632/PVEK) with an ant-CD47 antibody or antigen-binding fragment thereof (e.g., magrolimab) are provided. Methods of administering the combinations to treat hematological mali...
|
|
WO/2024/119769A1 |
The present invention relates to preparation and use of a transgenic CAR-NK cell. The transgenic CAR-NK cell expresses a chimeric antigen receptor and a chemokine receptor, the chemokine receptor including at least one of CXCR2, CXCR6, C...
|
|
WO/2024/123779A1 |
The present disclosure relates to a cancer treatment delivery method that may include preparing a cancer treatment delivery component that may include a carbon-based nanomaterial composition and a cancer treatment composition attached to...
|
|
WO/2024/120519A1 |
Provided are a compound represented by formula (I) and/or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, as well as a preparation method therefor, a pharmaceutical composition comprising the compound of...
|
|
WO/2024/121259A1 |
A compound of formula (I) [MCL-1 ligand prodrug moiety] – [linker] – [ligase ligand moiety] (I) or a salt, solvate, hydrate or isomer thereof, wherein [MCL-1 ligand prodrug moiety] is e.g. and its use in the treatment of cancer.
|
|
WO/2024/123038A1 |
The objective of the present invention is to provide a novel 2-((trans-4-(4-aryloxy)cyclohexyl)amino)quinazolinone derivative which exhibits anti-cancer activity through eIF2α phosphorylation efficacy. The novel synthesized derivative e...
|
|
WO/2024/123872A1 |
The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy—induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.
|
|
WO/2024/123048A1 |
The present invention relates to a genetic construct for encoding a fusion protein having the ability to bind to a strep-tag binding material in a strain targeted by tumor cells, and a recombinant expression vector, a recombinant strain ...
|
|
WO/2024/122961A1 |
The objective of the present invention is to provide a novel 2-((trans-4-(4-aryloxy)cyclohexyl)amino)quinazolinone derivative which exhibits anti-cancer activity through eIF2α phosphorylation efficacy. The novel synthesized derivative e...
|
|
WO/2024/124084A1 |
The present disclosure provides methods of administering belumosudil to patients with multiple myeloma.
|
|
WO/2024/121861A1 |
The invention relates to the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (preferably recurrent squamous cell carcinoma of the head and neck) with a compound which is (3-ethynyl-phenyl)-[7- methox...
|
|
WO/2024/121126A1 |
The present disclosure relates to monoclonal antibodies directed against the external loop of SLC1A4, which monoclonal antibodies are preferably human monoclonal antibodies. The present disclosure also relates to the therapeutic use of t...
|
|
WO/2024/120433A1 |
The invention relates to fused cyclic compounds, a composition containing the same and the use thereof.
|
|
WO/2024/121711A1 |
The disclosure provides methods of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) by the administration of one or more BCMA antagonists.
|
|
WO/2024/123029A1 |
The present invention relates to an aqueous gemcitabine solution preparation and a preparation method therefor, the aqueous gemcitabine solution preparation comprising, as an active ingredient, gemcitabine or a pharmaceutically acceptabl...
|
|
WO/2024/120466A1 |
Provided herein are monosaccharides, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for cell labeling for diagnostic and/or therapeutic applications.
|
|
WO/2024/120448A1 |
An HDAC inhibitor and the use thereof. Specifically, the present invention relates to a compound as represented by general formula (1) and a preparation method therefor, and the use of the compound of general formula (1) and each isomer,...
|
|
WO/2024/121379A1 |
The invention provides a compound according to formula (I) as specified in the application and a B-cell targeting agent for use in a method for the treatment and/or prophylaxis of cancer, wherein in the method, the B-cell targeting agent...
|
|
WO/2024/124182A1 |
The present disclosure provides unit dosage forms comprising Compound 1 (I) Compound 1 or a pharmaceutically acceptable salt thereof, that are useful for treatment of estrogen receptor mediator diseases, disorders, and conditions. The pr...
|
|
WO/2024/121385A1 |
This document relates to methods of immunotherapy comprising administering CAR-T cells to a subject in need thereof, in particular a 2-dose regimen of CAR-T therapy, and materials and compositions to carry out such methods.
|
|
WO/2024/121349A1 |
The invention provides a method of treating a haematological cancer in a patient, the method comprising the following steps: i. quantifying the level of T-cell function of the patient; ii. if the level of T-cell function of the patient i...
|
|
WO/2024/121427A1 |
The present disclosure relates to compounds that are IL-17A modulators. The compounds have the structural Formula I defined herein. The present disclosure also relates to processes for the preparation of these compounds, to pharmaceutica...
|
|
WO/2024/123700A1 |
This disclosure relates to certain compounds that are inhibitors of histone deacetylases (HDACs), as well as compositions thereof and methods of using such compounds to treat diseases, such as those described herein.
|
|
WO/2024/120084A1 |
The present application relates to a composition, comprising i) an antibody that specifically binds to CD24 or an antigen-binding moiety thereof, and ii) an antibody capable of blocking PD-1-PD-L1 binding/interaction or an antigen-bindin...
|
|
WO/2024/123149A1 |
The present invention relates to a method for preparing endocannabinoid analogues, and use thereof, the method comprising a step of using a lipase so as to perform amidation on a C2-6 aminoalcohol and a vegetable oil containing neutral f...
|
|
WO/2024/120455A1 |
Disclosed in the present application are a phosphatidylamine compound comprising a plurality of tertiary amino group structures, as well as a composition and use thereof. The phosphatidylamine compound is a phospholipid compound comprisi...
|
|
WO/2024/123180A1 |
The current invention relates to the identification of specific T cells, antigen-presenting cells (APC) and/or tumor cells in T cell clusters identified in a sample obtained from a subject having cancer or being suspected of having cance...
|
|
WO/2024/123412A1 |
Ferroptosis inducer compounds capable of killing cancer cells, along with methods of making and using the same, are described.
|
|
WO/2024/119375A1 |
JAK inhibitor long-acting sustained-release microspheres, a preparation method therefor, and use thereof. A JAK inhibitor and a biocompatible polymer (containing a surfactant) are separately dissolved in an organic solvent, and then mixe...
|
|
WO/2024/120438A1 |
A solid dispersion, a preparation method therefor, and use thereof. The solid dispersion comprises an active ingredient: a compound of formula A or a derivative thereof, a crystal form thereof, an amorphous form thereof, or a pharmaceuti...
|
|
WO/2024/120467A1 |
Provided herein are monosaccharides, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for cell labeling for diagnostic and/or therapeutic applications.
|
|
WO/2024/121072A1 |
The present invention relates to a compound having the formula (I) or one of its pharmaceutically acceptable salts, for use in treating a pathology due to a deregulation of MKlp2 or a pathology wherein the MKlp2 pathway is deregulated, p...
|
|
WO/2024/121311A1 |
The present invention relates to a bispecific antibody comprising at least one binding portion which binds to human CD47 and at least two binding portions which bind to human CD38, for use in the treatment of Acute myeloid leukemia or T-...
|
|
WO/2024/123175A1 |
The present invention provides a pharmaceutical combination for use in treating cancer comprising an ITK inhibitor and an immune checkpoint inhibitor, wherein the ITK inhibitor is formulated for intermittent administration or for adminis...
|
|
WO/2024/121395A1 |
The present invention provides compounds I that are active as IAP inhibitors and which may be used for the treatment of HIV infections and/or cancer. The present invention also provides pharmaceutical compositions comprising such compoun...
|
|
WO/2024/121722A1 |
The present disclosure relates to a method of treating prostate-specific membrane antigen (PSMA)-positive progressive metastatic castration-resistant prostate cancer (mCRPC) by administering to a taxane-naïve patient, who has progressed...
|
